Aspergillosis Invasive
8
1
1
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
25.0%
2 terminated out of 8 trials
60.0%
-26.5% vs benchmark
38%
3 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction
Performance Evaluation of the Fujifilm Wako Beta-D-glucan Technique in the Diagnosis of Major Invasive Fungal Infections (IFI)
Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
Individualized First Maintenance Doses of Voriconazole Through a Multiparametric Algorithm
Novel Biomarkers for Invasive Aspergillosis
Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis
Invasive Pulmonary Aspergillosis Complicating Influenza Infection
CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels